China Resources 39: 2025 Net Profit of 3.42 Billion Yuan, Obtains Multiple Classic Formula Drug Registration Certificates

LightningPacketLoss · 2026-03-21T09:06:22+00:00

China Resources 39 Holdings' 2025 annual report shows that the company's operating revenue reached 31.6 billion yuan, a year-over-year increase of 14.4%; net profit attributable to parent company shareholders was 3.42 billion yuan, an increase of 1.6%. The company made progress in traditional Chinese medicine R&D and innovative drug development, forming a strategy centered on CHC, continuing to advance the Healthy China strategy and brand building, with stable business operations.

LightningPacketLoss

2026-03-21 09:06:22

Abstract generation in progress

China Resources Sanjiu announced its 2025 annual report, stating that the company’s operating revenue was 31.6 billion yuan, up 14.4% year-on-year; net profit attributable to shareholders was 3.42 billion yuan, up 1.6%; net profit after deducting non-recurring gains and losses was 3.13 billion yuan, up 0.5%; net operating cash flow was 5.513 billion yuan, a 25.2% increase; EPS (fully diluted) was 2.0556 yuan.

In the 2025 annual report, the company mentioned that, guided by the corporate mission of “Caring for Public Health, Creating a Better Life Together,” it actively implements the “Healthy China” strategy and has initiated the “High-Quality Development Plan for the Traditional Chinese Medicine Industry Chain,” promoting the upgrade of the entire Chinese medicine industry chain. During the reporting period, the company received multiple drug registration certificates for classic formulas, including Wen Jing Tang granules and Ban Xia Bai Zhu Tian Ma Tang granules, marking significant progress in its Chinese medicine R&D.

In terms of business layout, the company has formed an “One Core, Two Wings” strategy centered on CHC (Consumer Healthcare), with future plans to continue focusing on the coordinated development of consumer health and prescription drugs. The company has also increased investment in R&D, promoting the development and transformation of innovative drugs to maintain a leading position in a highly competitive market environment. Overall, the company’s business model and product lines remained stable during the reporting period, with ongoing efforts in innovation and brand building.

(China Resources Sanjiu Announcement)

(Editors: Yang Yan, Lin Chen)

Keywords:

Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes